{"disease":{"id":"treatment-of-unresectable-or-metastatic-colorectal-cancer","name":"Treatment of unresectable or metastatic colorectal cancer","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"capecitabine","indication_name":"Treatment of unresectable or metastatic colorectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"folfiri","indication_name":"Treatment of unresectable or metastatic colorectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Folfiri","generic_name":"folfiri","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication and repair","drug_class":"chemotherapy","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"capecitabine","guideline_body":"FDA label","recommendation":"Capecitabine is indicated for the treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen.","line_of_therapy":"1L|2L|3L+","evidence_grade":"not specified","guideline_year":null},{"drug_id":"capecitabine","guideline_body":"FDA label","recommendation":"Capecitabine is indicated for the treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"capecitabine","guideline_body":"FDA label","recommendation":"Capecitabine is indicated for the treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}